WO2013016544A4 - Templated islet cells and small islet cell clusters for diabetes treatment - Google Patents

Templated islet cells and small islet cell clusters for diabetes treatment Download PDF

Info

Publication number
WO2013016544A4
WO2013016544A4 PCT/US2012/048352 US2012048352W WO2013016544A4 WO 2013016544 A4 WO2013016544 A4 WO 2013016544A4 US 2012048352 W US2012048352 W US 2012048352W WO 2013016544 A4 WO2013016544 A4 WO 2013016544A4
Authority
WO
WIPO (PCT)
Prior art keywords
well
divot
xenobiotic
divots
top surface
Prior art date
Application number
PCT/US2012/048352
Other languages
French (fr)
Other versions
WO2013016544A3 (en
WO2013016544A2 (en
Inventor
Lisa A. Stehno-Bittel
Karthik Ramachandran
Original Assignee
University Of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Kansas filed Critical University Of Kansas
Priority to JP2014523006A priority Critical patent/JP2014521335A/en
Priority to CA2842695A priority patent/CA2842695C/en
Priority to EP12818108.8A priority patent/EP2736536A4/en
Priority to EP18186206.1A priority patent/EP3498300A1/en
Publication of WO2013016544A2 publication Critical patent/WO2013016544A2/en
Publication of WO2013016544A3 publication Critical patent/WO2013016544A3/en
Publication of WO2013016544A4 publication Critical patent/WO2013016544A4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/72—Chitin, chitosan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2535/00—Supports or coatings for cell culture characterised by topography

Abstract

Substrates and devices for culturing cells are disclosed, along with methods of using the same. The substrates and devices include top surfaces with one or more divots disposed therein. Each divot is defined by an opening in the top surface, a rounded bottom surface spaced from the opening, and an interior side-wall surface extending between the rounded bottom surface and the opening. The top surface of the substrates and devices are optionally walled to form wells containing one or more divots. The substrates and devices may be used for reaggregating cells, for example, to form small islet cell clusters and for high throughput testing methodologies.

Claims

AMENDED CLAIMS
received by the International Bureau on 16 April 2013 (16.04.2013)
I . -8. (Canceled)
9. A device for culturing cells, comprising:
a substrate comprising
a substantially planar top surface,
a plurality of divots disposed within the top surface, each divot defined by an opening in the top surface, a rounded bottom surface spaced from the opening, and an interior side-wall surface extending between the rounded bottom surface and the opening, wherein each divot has a depth of between 50 - 300 μηι (± 20%) and a diameter of between 100 - 1000 μπι (± 20%); and
at least one well disposed on the top surface, the well comprising a peripheral side-wall extending upwardly from the top surface in a direction generally perpendicular to a plane defined by the top surface and forming an interior space within the well,
wherein the peripheral side-wall circumscribes the opening of at least one divot to prevent liquid communication between the at least one divot within the well periphery and an adjacent divot outside of the well.
10. The device of claim 9 further comprising a plurality of wells.
I I . The device of claim 10, wherein each well comprises 1-14 divots.
12. The device of claim 9 further comprising islet cells.
13. The device of claim 12, wherein the islet cells form small islet cell clusters with a diameter of less than 125 μη .
14. The device of claim 9 further comprising reaggregated 3-dimensional cell clusters.
15. A device for culturing cells, comprising:
71 a substrate having a substantially planar top surface;
a side-wall extending upwardly from the surface in a direction generally perpendicular to a plane defined by the top surface and circumscribing a portion of the surface, said side- wall and top surface cooperatively forming a liquid impermeable well, wherein the well has a bottom surface corresponding to the portion of the top surface circumscribed by the side- wall; and
a divot disposed in the bottom surface of the well,
wherein the divot is defined by an opening in the bottom surface of the well, a rounded bottom surface spaced from the opening, and an interior side-wall surface extending between the rounded bottom surface and the opening.
16. The device of claim 15, wherein the divot has a depth of less than 300 μηι (± 20%) and a diameter of 50 - 300 μηι (±20%).
17. The device of claim 15 further comprising a plurality of wells, wherein each well comprises 1-14 divots.
18. The device of claim 17, wherein each divot comprises a 3 -dimensional cell spheroid.
19. A method of evaluating a xenobiotic for biological activity, said method comprising: providing a device according to claim 15, said device comprising a plurality of wells, each well comprising 1 or more divots;
culturing cells in said divots to form a 3 -dimensional cell cluster in each divot;
adding a first xenobiotic to at least a first well, wherein said first xenobiotic comes into contact with at least a first cell cluster in said first well; and
evaluating the effects of said first xenobiotic on said first cell cluster.
20. The method of claim 19, wherein said first well comprises a plurality of divots, said first xenobiotic coming into contact with a first plurality cell clusters, each cell cluster being in respective divots in said first well, said method further comprising determining the average effect of said first xenobiotic on said first plurality of cell clusters.
72
21. The method of claim 19, further comprising:
adding a second xenobiotic to at least a second well, wherein said second xenobiotic comes into contact with at least a second cell cluster in said second well; and
evaluating the effects of said second xenobiotic on said second cell cluster.
22. The method of claim 21, wherein said second well comprises a plurality of divots, said second xenobiotic coming into contact with a second plurality cell clusters, each cell cluster being in respective divots in said second well, said method further comprising determining the average effect of said second xenobiotic on said second plurality of cell clusters.
23. The method of claim 21 , wherein said first and second xenobiotics are added to said device substantially simultaneously.
24. The method of claim 19, wherein each divot comprises a single 3 -dimensional cell cluster.
25. The method of claim 19, wherein said 3-dimensional cell clusters are islets.
73
PCT/US2012/048352 2011-07-27 2012-07-26 Templated islet cells and small islet cell clusters for diabetes treatment WO2013016544A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2014523006A JP2014521335A (en) 2011-07-27 2012-07-26 Islet cells and small islet cell cluster templates for the treatment of diabetes
CA2842695A CA2842695C (en) 2011-07-27 2012-07-26 Method of evaluating a xenobiotic for biological activity using one or more divots
EP12818108.8A EP2736536A4 (en) 2011-07-27 2012-07-26 Templated islet cells and small islet cell clusters for diabetes treatment
EP18186206.1A EP3498300A1 (en) 2011-07-27 2012-07-26 Templated islet cells and small islet cell clusters for diabetes treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161512303P 2011-07-27 2011-07-27
US61/512,303 2011-07-27
US201213482671A 2012-05-29 2012-05-29
US13/482,671 2012-05-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP18186206.1A Previously-Filed-Application EP3498300A1 (en) 2011-07-27 2012-07-26 Templated islet cells and small islet cell clusters for diabetes treatment

Publications (3)

Publication Number Publication Date
WO2013016544A2 WO2013016544A2 (en) 2013-01-31
WO2013016544A3 WO2013016544A3 (en) 2013-04-25
WO2013016544A4 true WO2013016544A4 (en) 2013-06-13

Family

ID=46275980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048352 WO2013016544A2 (en) 2011-07-27 2012-07-26 Templated islet cells and small islet cell clusters for diabetes treatment

Country Status (4)

Country Link
EP (2) EP2736536A4 (en)
JP (1) JP2014521335A (en)
CA (1) CA2842695C (en)
WO (1) WO2013016544A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236952B2 (en) 2013-03-15 2019-10-17 Miromatrix Medical Inc. Use of perfusion decellularized liver for islet cell recellularization
JP6405752B2 (en) * 2014-07-01 2018-10-17 大日本印刷株式会社 Cell culture vessel

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK402984D0 (en) 1984-08-23 1984-08-23 Nordisk Insulinlab PROCEDURE FOR PROMOTING INSULIN-PRODUCING CELLS
EP0363125A3 (en) 1988-10-03 1990-08-16 Hana Biologics Inc. Proliferated pancreatic endocrine cell product and process
US5164000A (en) 1991-06-27 1992-11-17 Gamblin Rodger L Lithographic printing fountain solution
US5280038A (en) 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6703017B1 (en) 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5670545A (en) 1996-02-09 1997-09-23 Board Of Regents Of The University Of Colorado Method for the treatment of ischemic disease and reperfusion injury and the prevention of the adverse effects of reactive oxygen species
US6783954B2 (en) 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US6103255A (en) * 1999-04-16 2000-08-15 Rutgers, The State University Porous polymer scaffolds for tissue engineering
US20070122904A1 (en) * 2000-09-29 2007-05-31 Unisearch Limited Method and apparatus for culturing cells
US7786257B2 (en) 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US8361781B2 (en) * 2006-01-24 2013-01-29 Brown University Cell aggregation and encapsulation device and method
US8735154B2 (en) * 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
US8663626B2 (en) * 2007-03-12 2014-03-04 Technion Research & Development Foundation Limited Vascularized islets and methods of producing same
EP2246414B1 (en) * 2008-02-06 2018-04-04 Public University Corporation Yokohama City University Cell culture method and screening method
EP2286822A1 (en) * 2009-08-17 2011-02-23 Universiteit Twente Diabetes treatment

Also Published As

Publication number Publication date
CA2842695A1 (en) 2013-01-31
WO2013016544A3 (en) 2013-04-25
JP2014521335A (en) 2014-08-28
CA2842695C (en) 2021-01-12
EP3498300A1 (en) 2019-06-19
EP2736536A2 (en) 2014-06-04
WO2013016544A2 (en) 2013-01-31
EP2736536A4 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
WO2011011062A3 (en) Flow cell device
WO2008014136A3 (en) Octagon transfer chamber
WO2009034927A1 (en) Cell culture instrument and cell culture method using the same
WO2007101130A3 (en) Compositions and methods useful for culturing differentiable cells
JP2011037847A5 (en)
IL214547A (en) Microarray comprising a plurality of microchannels and a plurality of microwell sets
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
WO2015035239A3 (en) Reagents and methods for screening mps i, ii, iiia, iiib, iva, vi, and vii
WO2011116922A3 (en) Thermoreactive substrate with microgels, method for its preparation, and culture method for biological cells
RU2011124902A (en) METHODS AND COMPOSITIONS FOR ATTACHING AND CULTIVATING CELLS ON FLAT CARRIERS
WO2010079058A3 (en) Methods for conducting cellular assays
SG11201900715QA (en) Method for culturing cell, and method for removing and killing cell from cell suspension
WO2014143981A8 (en) Deposition and imaging of particles on planar substrates
WO2013016544A4 (en) Templated islet cells and small islet cell clusters for diabetes treatment
JP2013516174A5 (en)
WO2009124296A3 (en) Method of enhancing enzyme activity
WO2010002503A3 (en) Electrobiochemical reactor
WO2012125645A3 (en) Inactive dummy pixels
Qu et al. Secondary metabolites of halotolerant fungus Penicillium chrysogenum HK14-01 from the Yellow River Delta area
WO2009152183A3 (en) System and method for hybridization slide processing
TW201144859A (en) E-ink display device and manufacturing method thereof
Rizk et al. An indigenous inland genotype of the black yeast Hortaea werneckii inhabiting the great pyramid of Giza, Egypt
CN209428538U (en) A kind of tissue culture plate
CN205275566U (en) Fixing device
Zaveri et al. Assessment of Enzyme Activity and functional microbial diversity in coastal and desert soil ecosystems of Gujarat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12818108

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2842695

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014523006

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE